{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:35:09Z","timestamp":1777124109215,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Grant-in-Aid for Challenging Exploratory Research","award":["15K1573"],"award-info":[{"award-number":["15K1573"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.yexcr.2019.01.016","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T18:20:47Z","timestamp":1548440447000},"page":"210-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects"],"prefix":"10.1016","volume":"376","author":[{"given":"Katsuhiro","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kasamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Toeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Shiiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tanzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2019.01.016_bib1","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"Cancer Stat. CA Cancer J. Clin."},{"key":"10.1016\/j.yexcr.2019.01.016_bib2","doi-asserted-by":"crossref","DOI":"10.7314\/APJCP.2013.14.10.5567","article-title":"Epidemiology of oral cancer in Asia in the past decade\u00a0\u2013 an update (2000\u20132012)","author":"Rao","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.yexcr.2019.01.016_bib3","article-title":"Squamous cell carcinoma of the oral cavity: clinical and pathological aspects","author":"Fronie","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2009.02.027","article-title":"EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma","author":"Ryott","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx439","article-title":"A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","author":"Bossi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.01.016_bib7","article-title":"Therapy for metastatic or recurrent squamous cell carcinoma of the head and neck","author":"Systemic","year":"2015","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.yexcr.2019.01.016_bib8","article-title":"Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor: systemic review and meta-analysis","author":"Su","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.yexcr.2019.01.016_bib9","article-title":"National guideline clearinghouse, Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer","volume":"11","author":"Tappenden","year":"2007","journal-title":"Heal. Technol. Assess."},{"key":"10.1016\/j.yexcr.2019.01.016_bib10","first-page":"204","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","volume":"22","author":"SALTZ","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28767","article-title":"A randomized phase 2 trial of gemcitabine\/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma","author":"Hussain","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI31680","article-title":"Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia","author":"Groenestege","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexcr.2019.01.016_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2011.159","article-title":"Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells","author":"Uzawa","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2019.01.016_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JB.01896-14","article-title":"Defect in the formation of 70S ribosomes caused by lack of ribosomal protein L34 can be suppressed by magnesium","author":"Akanuma","year":"2014","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2017.08.028","article-title":"Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration","author":"Saito","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.yexcr.2019.01.016_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29013","article-title":"Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)","author":"Li-Weber","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2017.12.138","article-title":"Evaluation of tryptophan-aspartic acid repeat-containing protein 34 as a novel tumor-suppressor molecule in human oral cancer","author":"Yamamoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2019.01.016_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/mc.22889","article-title":"FBLIM1 enhances oral cancer malignancy via modulation of the epidermal growth factor receptor pathway","author":"Toeda","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.yexcr.2019.01.016_bib20","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.4049\/jimmunol.174.8.5047","article-title":"ERK1\/2 regulates epidermal chemokine expression and skin inflammation","volume":"174","author":"Pastore","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.21988","article-title":"Up-regulation of TRPM6 transcriptional activity by AP-1 in renal epithelial cells","author":"Ikari","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119028","article-title":"Flavaglines stimulate transient receptor potential melastatin type 6 (TRPM6) channel activity","author":"Blanchard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2019.01.016_bib23","doi-asserted-by":"crossref","DOI":"10.1179\/1973947813Y.0000000155","article-title":"Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials","author":"Qi","year":"2014","journal-title":"J. Chemother."},{"key":"10.1016\/j.yexcr.2019.01.016_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","author":"Garden","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib25","doi-asserted-by":"crossref","DOI":"10.1517\/14740338.2011.606213","article-title":"Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies","author":"Petrelli","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.yexcr.2019.01.016_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2016.313","article-title":"FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer","author":"Marzi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0203402","article-title":"EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer","volume":"13","author":"Ma","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2019.01.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2017.12.008","article-title":"EGFR transactivation is involved in TNF-\u03b1-induced expression of thymic stromal lymphopoietin in human keratinocyte cell line","author":"Segawa","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.yexcr.2019.01.016_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.1988.tb01775.x","article-title":"The microbial colonization of inflamed acne vulgaris lesions","author":"Leeming","year":"1988","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-015-0072-7","article-title":"p38 MAP kinase inhibition reduces propionibacterium acnes-induced inflammation in vitro","author":"Li","year":"2015","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.yexcr.2019.01.016_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dji242","article-title":"Cetuximab therapy and symptomatic hypomagnesemia","author":"Schrag","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.yexcr.2019.01.016_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2009.03.012","article-title":"Electrolyte disorders related to EGFR-targeting drugs","author":"Izzedine","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(07)70108-0","article-title":"Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study","author":"Tejpar","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-014-1647-7","article-title":"TRPM6 kinase activity regulates TRPM7 trafficking and inhibits cellular growth under hypomagnesic conditions","author":"Brandao","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.yexcr.2019.01.016_bib35","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2008030327","article-title":"EGF increases TRPM6 activity and surface expression","author":"Thebault","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib36","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1074\/jbc.275.16.12266","article-title":"Urokinase plasminogen activator\/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutivep38?? Mitogen-activated protein kinase activity","volume":"275","author":"Huang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2019.01.016_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/1947601913507951","article-title":"Role of p38 MAP kinase signal transduction in solid tumors","author":"Koul","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib38","doi-asserted-by":"crossref","DOI":"10.1042\/BST20110676","article-title":"Roles of p38 MAPKs in invasion and metastasis","author":"del Barco Barrantes","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.yexcr.2019.01.016_bib39","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.20522","article-title":"Long-term activation of SAPK\/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance","volume":"112","author":"Brozovic","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib40","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2014.2490","article-title":"Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin resistant ovarian cancer","author":"Xie","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.yexcr.2019.01.016_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/aps.2014.62","article-title":"Crotoxin induces apoptosis and autophagy in human lung carcinoma cells in vitro via activation of the p38MAPK signaling pathway","author":"Han","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.yexcr.2019.01.016_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0854.2006.00420.x","article-title":"Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization","author":"Vergarajauregui","year":"2006","journal-title":"Traffic"},{"key":"10.1016\/j.yexcr.2019.01.016_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bbrc.2008.03.002","article-title":"TRPM6 expression and cell proliferation are up-regulated by phosphorylation of ERK1\/2 in renal epithelial cells","volume":"369","author":"Ikari","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2019.01.016_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2012.07.012","article-title":"The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2","author":"Polier","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.yexcr.2019.01.016_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.28521","article-title":"The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM\/ATR-mediated Chk1\/2 cell cycle checkpoints","author":"Neumann","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.22883","article-title":"The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities","author":"Zhu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib47","article-title":"Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial\/apoptosome pathway without activation of executioner caspase-3 or -7","author":"Kim","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.yexcr.2019.01.016_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.20033","article-title":"Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells","author":"Hausott","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2019.01.016_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-09-175430","article-title":"The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo","author":"Lucas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2019.01.016_bib50","article-title":"Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity","author":"Li","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719300217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719300217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:23:03Z","timestamp":1757996583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482719300217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0014482719300217"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.01.016","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}